CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) today announced that it will make
multiple presentations, including two oral abstracts, that will be
featured at the 35th International Congress of the
International Society of Blood Transfusion (ISBT) in Toronto, Canada
from June 2nd to June 6th, 2018. ISBT is one of
the premier congresses in transfusion medicine.
Cerus will also be hosting a symposium, Pathogen Inactivation Around
the World: Setting the Standard for Blood Safety, at ISBT on Tuesday
June 5th from 12:00 pm ET to 1:30 pm ET. This symposium will
provide a global perspective on the use and evolution of pathogen
inactivation. Key opinion leaders from Europe, Latin America and North
America will discuss the need for pathogen inactivation, experiences in
implementation, and clinical impact, all of which may have unique
aspects specific to given regions.
“This year’s ISBT will be the first opportunity for Cerus and
investigators from the SPARC study, our European chronic anemia trial in
thalassemia patients, to present results. We are looking forward to
sharing safety data with the scientific and clinical community,” said
Dr. Richard Benjamin, Cerus’ chief medical officer.
Cerus and its clinical partners will present data on an array of topics
including the potential operational and cost efficiencies provided by
Cerus’ Dual Storage processing set for platelets, the pathogen
inactivation efficacy of the INTERCEPT Blood System, and the viability
of INTERCEPT-treated platelets stored for seven days.
Key presentations include:
-
No INTERCEPT (S-303/Glutathione)-Specific Antibodies Detected in a
Phase III, Randomized, Controlled Study to Evaluate
Pathogen-Inactivated Red Blood Cells in Thalassemia Major Patients
(SPARC), by C Geisen et al.
-
Three Years Routine Experience of Manual Production of Double-Dose
Buffy Coat Platelets and Pathogen Inactivation System INTERCEPT:
Impact on Economy, Blood Safety and Blood Component Quality, by
HS Ahlzén and L Larsson
-
Amotosalen/UVA Treatment Can Inactivate Klebsiella Pneumoniae
in WB-Derived PC To Effective Sterility, After 7 Days of Storage, by
N Patel et al.
-
Amotosalen-UVA Inactivates High Levels of Treponema Pallidum
in Platelet Concentrates Suspended in 100% Plasma, by A
Laughhunn et al.
-
Inactivation of Trypanosoma Cruzi with Amotosalen/UVA in
Platelet Components and Apheresis Plasma,
by A Laughhunn, F
Buckner, R Gillespie, P Bringmann, and A Stassinopoulos
-
In Vitro
Characterization of Amotosalen-UVA Platelet
Components Stored for 7 Days,
by S Yegneswaran et al.
A full list of presentation times, abstracts and details on the
symposium can be viewed at http://interceptbloodsystem.com/en/insight/isbt-2018.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180601005205/en/
Cerus Corporation
Tim Lee, 925-288-6137
Investor Relations
Director
Source: Cerus Corporation